SPC329

Delafloxasín eða lyfjafræðilega viðunandi salt eða ester þar af, þar með talið delafloxasínmeglúmín

  • Status:
    Veitt
  • Application date:
    9.2.2021
  • Application published:
    15.3.2021
  • Grant published:
    15.4.2023
  • Max expiry date:
    22.9.2034
  • Medicine name:
    Quofenix
  • Medicine for children:
    No

Timeline

Today
9.2.2021Application
15.3.2021Publication
15.4.2023Registration
22.9.2034Expires

Marketing license

  • IS authorization number:
    EU/1/19/1393/001; EU/1/19/1393/002-007
  • Date:
    30.12.2019
  • Foreign authorization number:
    EU/1/19/1393
  • Date:
    16.12.2019

Owner

  • Name:
    Melinta Subsidiary Corp.
  • Address:
    389 Interpace Parkway, Suite 450, Parsippany, NJ 07054 US

Agent

  • Name:
    Árnason Faktor ehf.
  • Address:
    Guðríðarstíg 2-4, 113 Reykjavík

Patent

Deadlines

TypeDeadline until

Type: Frestur til að fara yfir drög að vottorði

Deadline until: 01.04.2023

Type: Frestur til að svara höfnun, fyrsti

Deadline until: 09.03.2023

Upload documents